Drug intelligence / Profile preview

PepFect14-mRNA nanoparticles

Development stage: Preclinical
Lead developer: Radboud University Medical Center
Modality: Peptides, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
Administration: Intraperitoneal, Subcutaneous

Overview

**PepFect14-mRNA nanoparticles** are experimental non-lipid messenger RNA delivery nanoparticles formed by electrostatic complexation of the amphipathic cell-penetrating peptide PepFect14 with an mRNA cargo. The PF14 carrier promotes cellular uptake and intracellular delivery of the encoded mRNA, enabling transient protein expression. In cell models, uptake has been associated principally with macropinocytosis and, depending on cell type, clathrin-mediated endocytosis. Preclinical studies have evaluated reporter-mRNA delivery in irritant contact dermatitis models after subcutaneous administration and in intraperitoneal ovarian cancer models. The term denotes a delivery-platform family rather than one defined medicinal product because the therapeutic protein and biological target depend on the particular mRNA cargo. ([frontiersin.org](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1219761/full))

Other names: PF14-mRNA nanoparticlesPF-14-mRNA nanoparticlesPF 14-mRNA nanoparticlesPF14/mRNA nanoparticlesPepFect 14-mRNA nanoparticlesPepFect14-mRNA nanoparticlesPepFect-14-mRNA nanoparticlesPepFect14 mRNA nanoparticlesPepFect-14 mRNA nanoparticlesPepFect 14 mRNA nanoparticles

Targets

MSR1 (Amyloid beta precursor protein binding family B member 3)Caveolae-mediated endocytic machinery

Beyond the preview

Go deeper on PepFect14-mRNA nanoparticles.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PepFect14-mRNA nanoparticles.

Explore the full profile